Kos Biotechnology Partners Backs Fathom Therapeutics

✦ Meridian Analysis

Kos Biotechnology Partners has closed an equity investment in Fathom Therapeutics, joining existing backers such as Sutter Hill Ventures to fund the company’s physics‑ and AI‑driven drug discovery platform. Kos is a global life‑sciences investment firm bridging the U.S. and European biopharma ecosystems. No valuation, size of the investment or financing structure was disclosed in the announcement. What remains undisclosed are the exact amount of capital committed, the implied valuation and any accompanying rights such as board representation or anti‑dilution protections. Details on the advisory banks, legal counsel and the timeline for subsequent financing rounds or partnership announcements would also be of interest to deal professionals monitoring the evolution of Fathom’s platform.

The Meridian Weekly